Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • Log out
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Cancer Research
Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Tumor Biology

Synthetic Matrix Metalloproteinase Inhibitors and Tissue Inhibitor of Metalloproteinase (TIMP)-2, but not TIMP-1, Inhibit Shedding of Tumor Necrosis Factor-α Receptors in a Human Colon Adenocarcinoma (Colo 205) Cell Line

Mark A. Lombard, Tanya L. Wallace, Marc F. Kubicek, Gary L. Petzold, Mark A. Mitchell, Susan K. Hendges and John W. Wilks
Mark A. Lombard
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tanya L. Wallace
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marc F. Kubicek
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gary L. Petzold
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark A. Mitchell
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susan K. Hendges
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John W. Wilks
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published September 1998
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

The solubilization of plasma membrane receptors through proteolytic cleavage of the ligand binding domain at the cell surface is an important mechanism for regulating cytokine function and receptor signaling. The inhibition of the shedding of a variety of receptors by synthetic inhibitors of the matrix metalloproteinases (MMPs) implicates metalloproteinases in this regulatory event. We examined the effects of two naturally occurring tissue inhibitors of metalloproteinases, TIMP-1 and TIMP-2, and several synthetic MMP inhibitors (MMPIs) on the shedding of both tumor necrosis factor α receptor type I (TNFα-RI; Mr 55,000) and TNFα-RII (Mr 75,000) by the Colo 205 human colon adenocarcinoma cell line. Culture of Colo 205 cells for 48 h resulted in the shedding of both TNFα-RI and TNFα-RII, as determined by ELISA. The shedding of TNFα receptors was not affected by TIMP-1 or protease inhibitors aprotinin, pepstatin, or leupeptin but was inhibited in a dose-dependent manner by the following synthetic MMPIs: batimastat and marimastat (BB-94 and BB-2516, respectively, British Biotech, Inc.); CT1418 (Celltech Therapeutics); CGS27023A (Novartis Pharmaceuticals); and RO31-9790 (Roche), with IC50s ranging from 3.2 to 38.0 µm. Similarly, TIMP-2 from two different sources reproducibly inhibited the shedding of both TNFα-RI and TNFα-RII in a dose-dependent manner (IC50 = 286 ± 33 nm for TNFα-RI shedding and 462 ± 52 nm for shedding of TNFα-RII). The inhibition of TNFα-RI shedding was confirmed in the SW626 human ovarian adenocarcinoma cell line. The synthetic MMPIs and TIMP-2, but not TIMP-1, also caused a dose-dependent increase in the number of TNFα receptors retained on the surface of Colo 205 cells, as determined by flow cytometry. Inhibition of TNFα receptor shedding with TIMP-2 occurs at molar concentrations 10–100 times less than those required with low molecular weight, synthetic MMPIs but at concentrations greater than those required to inhibit collagen degradation. Modulation of TNFα receptor shedding by TIMP-2 could have important implications for the pleiotropic effects of TNFα in both normal and malignant cells and for the pharmacological activity of synthetic MMPIs.

Footnotes

  • ↵1 To whom requests for reprints should be addressed, at Pharmacia & Upjohn, Inc., Cell and Molecular Biology, 7252-267-410, Kalamazoo, MI 49001-0199. Phone: (616) 833-7702; Fax: (616) 833-4255; E-mail: john.w.wilks@am.pnu.com.

  • Received March 16, 1998.
  • Accepted July 1, 1998.
  • ©1998 American Association for Cancer Research.
PreviousNext
Back to top
September 1998
Volume 58, Issue 17
  • Table of Contents
  • Table of Contents (PDF)
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)

Sign up for alerts

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Synthetic Matrix Metalloproteinase Inhibitors and Tissue Inhibitor of Metalloproteinase (TIMP)-2, but not TIMP-1, Inhibit Shedding of Tumor Necrosis Factor-α Receptors in a Human Colon Adenocarcinoma (Colo 205) Cell Line
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Synthetic Matrix Metalloproteinase Inhibitors and Tissue Inhibitor of Metalloproteinase (TIMP)-2, but not TIMP-1, Inhibit Shedding of Tumor Necrosis Factor-α Receptors in a Human Colon Adenocarcinoma (Colo 205) Cell Line
Mark A. Lombard, Tanya L. Wallace, Marc F. Kubicek, Gary L. Petzold, Mark A. Mitchell, Susan K. Hendges and John W. Wilks
Cancer Res September 1 1998 (58) (17) 4001-4007;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Synthetic Matrix Metalloproteinase Inhibitors and Tissue Inhibitor of Metalloproteinase (TIMP)-2, but not TIMP-1, Inhibit Shedding of Tumor Necrosis Factor-α Receptors in a Human Colon Adenocarcinoma (Colo 205) Cell Line
Mark A. Lombard, Tanya L. Wallace, Marc F. Kubicek, Gary L. Petzold, Mark A. Mitchell, Susan K. Hendges and John W. Wilks
Cancer Res September 1 1998 (58) (17) 4001-4007;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

Tumor Biology

  • Abstract 6119: RNAi rat models for drug discovery
  • Abstract 3834: Histone methyltransferase SET8 is regulated by miR-192/-215 and induces oncogene-induced senescence via p53-dependent DNA damage in human gastric carcinoma cells
  • Abstract 3788: CircHMGCS1 interacts with RNA binding protein HuR and maintains stem-like cells in gliomas
Show more Tumor Biology

Articles

  • Insights from Bcl-2 and Myc: Malignancy Involves Abrogation of Apoptosis as well as Sustained Proliferation
  • Mammary Gland Development, Reproductive History, and Breast Cancer Risk
  • Introduction of Stanley J. Korsmeyer
Show more Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement